CY1121690T1 - Κινολυλο-υδραζονες για την θεραπεια της φυματιωσης και σχετικων ασθενειων - Google Patents
Κινολυλο-υδραζονες για την θεραπεια της φυματιωσης και σχετικων ασθενειωνInfo
- Publication number
- CY1121690T1 CY1121690T1 CY20191100018T CY191100018T CY1121690T1 CY 1121690 T1 CY1121690 T1 CY 1121690T1 CY 20191100018 T CY20191100018 T CY 20191100018T CY 191100018 T CY191100018 T CY 191100018T CY 1121690 T1 CY1121690 T1 CY 1121690T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hydrazones
- quinolyl
- tuberculosis
- related diseases
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000008827 tuberculosis Diseases 0.000 title abstract 2
- 241000186362 Mycobacterium leprae Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση παρέχει κινολυλο-υδραζόνες του Τύπου I ή φαρμακευτικώς αποδεκτά άλατα, εστέρες, διαλύματα, ισομερή και προφάρμακα αυτών, καθώς και φαρμακευτικές συνθέσεις που περιέχουν αυτές τις ενώσεις για χρήση στην προφυλακτική και/ή θεραπευτική αγωγή της φυματίωσης και σχετικών ασθενειών, όπως είναι οι ασθένειες που προκαλούνται από μη φυματιδιακά μυκοβακτηρίδια και/ή που προκαλούνται από το Micobacterium leprae.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT106651A PT106651A (pt) | 2012-11-20 | 2012-11-20 | Quinolil hidrazonas para o tratamento de tuberculose e doenças relacionadas |
| PCT/PT2013/000069 WO2014081325A1 (en) | 2012-11-20 | 2013-11-20 | Quinolyl hydrazones for the treatment of tuberculosis and related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121690T1 true CY1121690T1 (el) | 2020-07-31 |
Family
ID=49876953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100018T CY1121690T1 (el) | 2012-11-20 | 2019-01-09 | Κινολυλο-υδραζονες για την θεραπεια της φυματιωσης και σχετικων ασθενειων |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9809550B2 (el) |
| EP (1) | EP2934528B1 (el) |
| BR (1) | BR112015011605A2 (el) |
| CY (1) | CY1121690T1 (el) |
| DK (1) | DK2934528T3 (el) |
| ES (1) | ES2710124T3 (el) |
| HR (1) | HRP20182198T1 (el) |
| HU (1) | HUE043021T2 (el) |
| LT (1) | LT2934528T (el) |
| MA (1) | MA38207B1 (el) |
| PL (1) | PL2934528T3 (el) |
| PT (2) | PT106651A (el) |
| RS (1) | RS58185B1 (el) |
| SI (1) | SI2934528T1 (el) |
| TR (1) | TR201900156T4 (el) |
| WO (1) | WO2014081325A1 (el) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080118576A1 (en) * | 2006-08-28 | 2008-05-22 | Dan Theodorescu | Prediction of an agent's or agents' activity across different cells and tissue types |
| JP5662940B2 (ja) * | 2008-11-20 | 2015-02-04 | パナセア バイオテック リミテッド | 新規な抗微生物薬 |
| EP2287149A1 (en) * | 2009-08-20 | 2011-02-23 | Max-Delbrück-Centrum Für Molekulare Medizin | Enhancers of protein degradation |
| EP2311457A1 (en) * | 2009-10-19 | 2011-04-20 | Forschungszentrum Borstel | Pharmaceutical compositions for treating infections with drug resistant mycobacteria |
| EP2627653B1 (en) * | 2010-10-13 | 2014-12-24 | Glaxo Group Limited | 3-amino-pyrazole derivatives useful against tuberculosis |
-
2012
- 2012-11-20 PT PT106651A patent/PT106651A/pt unknown
-
2013
- 2013-11-20 PL PL13811633T patent/PL2934528T3/pl unknown
- 2013-11-20 MA MA38207A patent/MA38207B1/fr unknown
- 2013-11-20 TR TR2019/00156T patent/TR201900156T4/tr unknown
- 2013-11-20 DK DK13811633.0T patent/DK2934528T3/en active
- 2013-11-20 US US14/443,787 patent/US9809550B2/en active Active
- 2013-11-20 RS RS20181598A patent/RS58185B1/sr unknown
- 2013-11-20 BR BR112015011605A patent/BR112015011605A2/pt not_active Application Discontinuation
- 2013-11-20 HU HUE13811633A patent/HUE043021T2/hu unknown
- 2013-11-20 EP EP13811633.0A patent/EP2934528B1/en active Active
- 2013-11-20 PT PT13811633T patent/PT2934528T/pt unknown
- 2013-11-20 ES ES13811633T patent/ES2710124T3/es active Active
- 2013-11-20 WO PCT/PT2013/000069 patent/WO2014081325A1/en active Application Filing
- 2013-11-20 LT LTEP13811633.0T patent/LT2934528T/lt unknown
- 2013-11-20 SI SI201331305T patent/SI2934528T1/sl unknown
-
2018
- 2018-12-31 HR HRP20182198TT patent/HRP20182198T1/hr unknown
-
2019
- 2019-01-09 CY CY20191100018T patent/CY1121690T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38207B1 (fr) | 2018-06-29 |
| PL2934528T3 (pl) | 2019-05-31 |
| HUE043021T2 (hu) | 2019-08-28 |
| BR112015011605A2 (pt) | 2017-07-11 |
| ES2710124T3 (es) | 2019-04-23 |
| WO2014081325A1 (en) | 2014-05-30 |
| TR201900156T4 (tr) | 2019-02-21 |
| US9809550B2 (en) | 2017-11-07 |
| RS58185B1 (sr) | 2019-03-29 |
| PT2934528T (pt) | 2019-03-20 |
| MA38207A2 (fr) | 2016-12-30 |
| EP2934528A1 (en) | 2015-10-28 |
| DK2934528T3 (en) | 2019-02-04 |
| PT106651A (pt) | 2014-05-20 |
| SI2934528T1 (sl) | 2019-03-29 |
| EP2934528B1 (en) | 2018-11-07 |
| HRP20182198T1 (hr) | 2019-02-22 |
| US20150299128A1 (en) | 2015-10-22 |
| LT2934528T (lt) | 2019-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1124652T1 (el) | Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
| CY1118129T1 (el) | 5-αλκυνυλ-πυριμιδινες | |
| ECSP16071151A (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| CO7141456A2 (es) | Derivados de aril-sultamo como moduladores de rorc | |
| CY1118662T1 (el) | Νεες δικυκλικες πυριδινονες | |
| BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| CY1120860T1 (el) | 2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο | |
| TR201900659T4 (tr) | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες |